SAN FRANCISCO -- Earlier in the pandemic, experts had hoped if we can get 75% of Americans vaccinated, we can contain the coronavirus. Thursday, we're at just over 50% vaccinated. But 75% is no longer ...
HOUSTON, Texas (KTRK) -- After seeing a significant decrease in COVID-19 cases, doctors say the Houston area is starting to see a slight uptick and they're associating the change with the fast-spread ...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will present new data from the Phase 2 SOLSTICE clinical trial evaluating the efficacy and safety profile of ...
Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency ...
SAN FRANCISCO (KGO) -- The Centers for Disease Control and Prevention (CDC) released new data Friday indicating the Delta variant is twice as infectious as previously thought, and a recent analysis ...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the ...
Estimates show the variant accounts for over 51% of all new cases nationwide. A highly contagious variant of the novel coronavirus that was initially identified in India is now the dominant strain in ...
Findings showed 100% of participants taking the tobevibart and elebsiran combination achieved an undetectable HDV RNA at week 24 that was sustained through week 60. The Food and Drug Administration ...
EMA grants Orphan Drug Designation to Ribo’s siRNA therapeutic RBD1016 for Hepatitis Delta Virus infection: Beijing, China Saturday, October 25, 2025, 17:00 Hrs [IST] Suzhou Rib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback